Lumosa Therapeutics Co (ROCO:6535) NonCurrent Deferred Liabilities: NT$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
70 GF Score
Price NT$88.30
GF Value NT$127.65
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co NonCurrent Deferred Liabilities?

Lumosa Therapeutics Co ROCO:6535 +0.23% 70 NonCurrent Deferred Liabilities is NT$0.00 Mil as of Mar. 2026. GuruFocus rates ROCO:6535 with a GF Score™ of 70/100 and a GF Value™ of NT$127.65 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Lumosa Therapeutics Co's non-current deferred liabilities for the quarter that ended in Mar. 2026 was NT$0.00 Mil.

Lumosa Therapeutics Co NonCurrent Deferred Liabilities Related Terms

Lumosa Therapeutics Co NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Lumosa Therapeutics Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumosa Therapeutics Co NonCurrent Deferred Liabilities Chart

Lumosa Therapeutics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lumosa Therapeutics Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6535
70GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of NT$0.00 Mil mean?
Lumosa Therapeutics Co (ROCO:6535) has a NonCurrent Deferred Liabilities of NT$0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Lumosa Therapeutics Co and its competitors.
Is Lumosa Therapeutics Co's NonCurrent Deferred Liabilities too high?
Lumosa Therapeutics Co's current NonCurrent Deferred Liabilities is NT$0.00 Mil. Overall, Lumosa Therapeutics Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's NonCurrent Deferred Liabilities compare to VRTX and REGN?
Lumosa Therapeutics Co's NonCurrent Deferred Liabilities of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current NonCurrent Deferred Liabilities is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$127.65, compared to a current price of NT$88.30 — trading 30.8% below its estimated fair value. The current NonCurrent Deferred Liabilities is NT$0.00 Mil. Lumosa Therapeutics Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current NonCurrent Deferred Liabilities is NT$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$88.30 is trading 30.8% below its estimated GF Value™ of NT$127.65. GuruFocus considers Lumosa Therapeutics Co to be Significantly Undervalued.

Key valuation signals for ROCO:6535:

  • NonCurrent Deferred Liabilities: NT$0.00 Mil
  • GF Value™: NT$127.65 vs. price of NT$88.30 (30.8% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score

Get the complete analysis for ROCO:6535

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$88.30
Price
NT$127.65
GF Value